Tags

Type your tag names separated by a space and hit enter

Is dienogest the best medical treatment for ovarian endometriomas? Results of a multicentric case control study.
Gynecol Endocrinol. 2020 Jan; 36(1):84-86.GE

Abstract

Ovarian endometriomas are common manifestations of endometriosis. Surgical excision has been shown to potentially decrease ovarian reserves. In this prospective study, we included 81 patients with ovarian endometriosis. 40 were treated with 2 mg of dienogest daily (DNG) and 41 were treated with cyclic oral estro-progestins (ethinyl estradiol 30 mcg [EE] plus dienogest 2 mg) (DNG + EE). Aim of the study was the effect of the treatment on the size of the endometriotic cysts. Further, in the symptomatic patients, follow-up included an evaluation of chronic pain before and during treatment. Both treatments were able to significantly decrease the pain in symptomatic patients with no statistical differences. The mean visual analog scale score at enrollment was 65 ± 14 and 70 ± 18, and there was significant improvement (19 ± 15, p < .001, DNG; 18 ± 12, p < .001, DNG + EE). The size of the endometrioma cysts were significantly reduced in the DNG group. The mean cyst diameter was 52 ± 22 mm at baseline and 32 ± 12 mm after six months of treatment (p < .001), yielding a 75% volume reduction in DNG group. The decrease in the size of endometrioma cysts observed in the women treated with only progestin could be noteworthy, as it may reduce the negative impacts on the affected ovary and avoid surgery.

Authors+Show Affiliations

Department of Obstetrics and Gynecology, Azienda Ospedaliero Universitaria, Presidio Policlinico di Monserrato, University of Cagliari, Monserrato, Italy.Department of Obstetrics and Gynecology, San Francesco Hospital, Nuoro, Italy.Department of Obstetrics and Gynecology, Azienda Ospedaliero Universitaria, Presidio Policlinico di Monserrato, University of Cagliari, Monserrato, Italy.Department of Obstetrics and Gynecology, University of Pisa, Pisa, Italy.Department of Molecular and Developmental Medicine, University of Siena, Siena, Italy.Department of Gynaecological Sciences and Human Reproduction, University of Padua, Padua, Italy.Macedonio Melloni Hospital, Milano, Italy.Department of Medical and Surgical Sciences, Institute of Obstetrics and Gynecology, University of Foggia, Foggia, Italy.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

31311360

Citation

Angioni, Stefano, et al. "Is Dienogest the Best Medical Treatment for Ovarian Endometriomas? Results of a Multicentric Case Control Study." Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology, vol. 36, no. 1, 2020, pp. 84-86.
Angioni S, Pontis A, Malune ME, et al. Is dienogest the best medical treatment for ovarian endometriomas? Results of a multicentric case control study. Gynecol Endocrinol. 2020;36(1):84-86.
Angioni, S., Pontis, A., Malune, M. E., Cela, V., Luisi, S., Litta, P., Vignali, M., & Nappi, L. (2020). Is dienogest the best medical treatment for ovarian endometriomas? Results of a multicentric case control study. Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology, 36(1), 84-86. https://doi.org/10.1080/09513590.2019.1640674
Angioni S, et al. Is Dienogest the Best Medical Treatment for Ovarian Endometriomas? Results of a Multicentric Case Control Study. Gynecol Endocrinol. 2020;36(1):84-86. PubMed PMID: 31311360.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Is dienogest the best medical treatment for ovarian endometriomas? Results of a multicentric case control study. AU - Angioni,Stefano, AU - Pontis,Alessandro, AU - Malune,Maria E, AU - Cela,Vito, AU - Luisi,Stefano, AU - Litta,Pietro, AU - Vignali,Michele, AU - Nappi,Luigi, Y1 - 2019/07/16/ PY - 2019/7/18/pubmed PY - 2019/7/18/medline PY - 2019/7/18/entrez KW - Endometriosis KW - dienogest KW - endometrioma KW - ultrasound SP - 84 EP - 86 JF - Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology JO - Gynecol. Endocrinol. VL - 36 IS - 1 N2 - Ovarian endometriomas are common manifestations of endometriosis. Surgical excision has been shown to potentially decrease ovarian reserves. In this prospective study, we included 81 patients with ovarian endometriosis. 40 were treated with 2 mg of dienogest daily (DNG) and 41 were treated with cyclic oral estro-progestins (ethinyl estradiol 30 mcg [EE] plus dienogest 2 mg) (DNG + EE). Aim of the study was the effect of the treatment on the size of the endometriotic cysts. Further, in the symptomatic patients, follow-up included an evaluation of chronic pain before and during treatment. Both treatments were able to significantly decrease the pain in symptomatic patients with no statistical differences. The mean visual analog scale score at enrollment was 65 ± 14 and 70 ± 18, and there was significant improvement (19 ± 15, p < .001, DNG; 18 ± 12, p < .001, DNG + EE). The size of the endometrioma cysts were significantly reduced in the DNG group. The mean cyst diameter was 52 ± 22 mm at baseline and 32 ± 12 mm after six months of treatment (p < .001), yielding a 75% volume reduction in DNG group. The decrease in the size of endometrioma cysts observed in the women treated with only progestin could be noteworthy, as it may reduce the negative impacts on the affected ovary and avoid surgery. SN - 1473-0766 UR - https://www.unboundmedicine.com/medline/citation/31311360/Is_dienogest_the_best_medical_treatment_for_ovarian_endometriomas_Results_of_a_multicentric_case_control_study L2 - http://www.tandfonline.com/doi/full/10.1080/09513590.2019.1640674 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.